comparemela.com

Latest Breaking News On - Cyril konto - Page 9 : comparemela.com

ICHNOS SCIENCES AND ALMIRALL ENTER INTO A LICENSING AGREEMENT FOR FIRST-IN-CLASS IL-1RAP ANTAGONIST MONOCLONAL ANTIBODY

Press release content from PR Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesComunidad autonoma de catalunaPablo divassonCyril kontoKarl ziegelbauerHead of communicationsPrnewswire ichnos sciences incCorporate communicationsIchnos sciencesIchnos sciences incSpanish stock exchangeCorporate affairsSciences incInvestor relationsLicensing agreements

ICHNOS SCIENCES AND ALMIRALL ENTER INTO A LICENSING AGREEMENT FOR FIRST-IN-CLASS IL-1RAP ANTAGONIST MONOCLONAL ANTIBODY

/PRNewswire/ Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, and Almirall S.A..

New yorkUnited statesComunidad autonoma de catalunaPablo divassonCyril kontoKarl ziegelbauerHead of communicationsPrnewswire ichnos sciences incCorporate communicationsIchnos sciencesIchnos sciences incSpanish stock exchangeCorporate affairsSciences incIchnos sciences inc

Glenmark s subsidiary, Ichnos Sciences and Almirall enter into an exclusive Licensing Agreement

Glenmark s subsidiary, Ichnos Sciences and Almirall enter into an exclusive Licensing Agreement
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Cyril kontoKarl ziegelbauerIchnos sciences incIchnos sciencesGlenmark pharmaceuticalsTime zoneSciences incGlenmark pharmaceuticals limited

ICHNOS SCIENCES PRESENTS PRECLINICAL DATA ON NOVEL ISB 1442 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AT THE ASH 2021 ANNUAL MEETING

/PRNewswire/ Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, today presented preclinical data that support.

New yorkUnited statesMario perroCyril kontoStefano sammicheliAmerican society of hematologyHead of communicationsPrnewswire ichnos sciences incIchnos sciences incIchnos sciencesCorporate affairsSciences incInnate cell engagersAmerican societyVice president oncologyInterim head

ICHNOS SCIENCES PRESENTS PRECLINICAL DATA ON NOVEL ISB 1442 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AT THE ASH 2021 ANNUAL MEETING

/PRNewswire/ Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, today presented preclinical data that support.

New yorkUnited statesMario perroCyril kontoStefano sammicheliAmerican society of hematologyHead of communicationsPrnewswire ichnos sciences incIchnos sciences incIchnos sciencesCorporate affairsSciences incInnate cell engagersAmerican societyVice president oncologyInterim head

vimarsana © 2020. All Rights Reserved.